By: Dave Rauf
“As we look ahead, we anticipate continued COVID-related inflationary and economic challenges in many of our markets.” —Kevin Guest, CEO, USANA
USANA Health Sciences reported a turbulent third quarter, as inflationary pressure coupled with COVID-19 disruptions in Asia led to double-digit sales and profit declines.
The weaker-than-expected performance during the quarter prompted USANA to lower its full-year guidance for 2022, as the company reported lower sales than the same period a year ago in all of its markets.
Please log in (or register) to continue viewing this content.